Markets Stocks Economy Crypto Earnings Banking Energy
Home Stocks Feature
Breaking · Stocks

Corporate Travel Management shares crash 85.6% after ASX trading resumes

Corporate Travel Management shares crash 85.6% after ASX trading resumes
Stocks · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Sep 3, 2026 3 min read

Shares in Corporate Travel Management (CTM) collapsed by 85.6% on Monday when trading resumed on the Australian Securities Exchange (ASX), wiping out billions in market value. The dramatic fall came after a year-long suspension that was triggered by delayed financial results and an accounting review of the company's UK operations.

Why the stock was suspended

CTM, a global corporate travel and event management company, was halted from trading in early 2024 after it failed to release its annual results on time. The delay was linked to an independent accounting review of its UK business, which raised questions about revenue recognition and other financial reporting practices.

During the suspension, investors were left in the dark about the company's financial health and the outcome of the review. The stock's resumption on Monday brought the first opportunity for shareholders to react to the news, and the market's verdict was harsh.

The 85.6% plunge is one of the steepest single-day declines for a major ASX-listed company in recent memory. It underscores how severely investor confidence can be damaged when a company's financial reporting is called into question.

What this means for investors

For everyday investors, the CTM collapse is a stark reminder of the risks associated with holding shares in companies that face accounting irregularities or prolonged trading halts. When a stock is suspended for an extended period, shareholders have no ability to sell, and the eventual resumption can lead to a violent repricing.

"This is a worst-case scenario for shareholders," said one market analyst, speaking on condition of anonymity. "The lack of transparency during the suspension, combined with the accounting review, has clearly shattered confidence in the company's numbers."

Investors who held CTM shares before the suspension have seen the value of their holdings plummet. The sharp decline also highlights the importance of diversification—holding a broad portfolio can help cushion the blow from a single stock's collapse.

The broader Australian market has been relatively resilient in recent sessions, with gold miners shining while heavyweight miners like BHP and Woodside weighed. However, the CTM crash is a reminder that individual stock risk can be severe, even in a stable market environment.

What to watch next

Investors will be closely watching CTM's next steps, including the release of its delayed financial results and any updates on the UK accounting review. The company may also face questions from regulators and potential class-action lawsuits from shareholders who suffered losses.

The situation is reminiscent of other corporate scandals where accounting issues led to massive share price declines. For example, Regis Healthcare shares plunged 34% earlier this year on funding concerns, though that decline was less severe.

CTM's collapse also comes amid a period of heightened scrutiny of corporate governance and financial reporting across global markets. European stocks have been steady as a bond selloff cools, but investor sentiment remains fragile, and any hint of accounting irregularities can trigger outsized reactions.

For those who own CTM shares, the immediate priority is to assess the company's fundamentals once the delayed results are finally published. For others, the episode serves as a cautionary tale about the risks of investing in companies with opaque financials or ongoing regulatory probes.

As always, it's important to remember that past performance is not indicative of future results, and that investing in individual stocks carries significant risk. Diversification and thorough research remain the cornerstones of a sound investment strategy.

More from this story

Next article · Don't miss

Chip and pharma projects could lift US factory construction above $200B

UBS expects US factory construction to rebound, led by new chip and pharma projects. Manufacturing-related building could top $200 billion by end of next year after a recent slowdown.

Read the story →
Chip and pharma projects could lift US factory construction above $200B